Venetoclax (VEN), a selective BCL-2 inhibitor predominantly metabolized by CYP3A4, is a cornerstone therapeutic for myeloid neoplasms (MNs). This evidence concerns the gene CYP3A4 and Melnick-Needles syndrome.